GlassScriptPhysician profile
Robert J Wielenga
NPI 1952469850
$9,609.59
in general payments reported to CMS, 2019-2025
49 companies · $870 in 2025
The $870 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $1,337 · 2021: $1,758 · 2022: $1,566 · 2023: $1,287 · 2024: $1,651 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,808.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,303.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,068.16 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $951.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $736.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $609.51 | 2021-2025 | Vraylar, Linzess, Ubrelvy |
| Janssen Pharmaceuticals, INC | $606.07 | 2019-2024 | Xarelto |
| Radius Health, INC. | $514.02 | 2021-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $354.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $318.56 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.23 | 2020-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $272.79 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $230.53 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.39 | 2019-2025 | Xifaxan |
| Pfizer INC. | $200.17 | 2019-2025 | |
| Horizon Therapeutics Plc | $168.31 | 2019-2021 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $164.18 | 2019-2023 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $142.97 | 2021-2025 | |
| Shield Therapeutics INC | $118.22 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $117.23 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $98.35 | 2022-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $92.83 | 2024 | Gvoke Hypopen |
| Allergan, INC. | $90.07 | 2019-2020 | |
| Dexcom, INC. | $84.31 | 2022-2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $78.09 | 2019-2021 | |
| Corcept Therapeutics | $67.92 | 2021 | |
| Scilex Pharmaceuticals INC. | $66.06 | 2023-2024 | Ztlido |
| Eisai INC. | $55.01 | 2021-2022 | |
| Lundbeck LLC | $53.01 | 2023-2024 | Rexulti |
| Nevro Corp. | $43.53 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $42.52 | 2021-2024 | Nuedexta |
| Exact Sciences Corporation | $38.42 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $32.25 | 2021-2022 | |
| Edwards Lifesciences Corporation | $29.86 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Averitas Pharma INC. | $28.33 | 2024 | Qutenza |
| Phathom Pharmaceuticals, INC. | $26.60 | 2024 | Voquezna |
| Astellas Pharma US INC | $24.27 | 2021 | |
| Azurity Pharmaceuticals, INC. | $24.02 | 2025 | Edarbi |
| Sk Life Science, INC. | $23.75 | 2021 | |
| Corium, LLC | $21.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.00 | 2022 | |
| Esperion Therapeutics, INC. | $19.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.46 | 2025 | Trintellix |
| Arbor Pharmaceuticals, INC. | $17.49 | 2019 | |
| Merck Sharp & Dohme LLC | $17.14 | 2021 | |
| Vifor Pharma, INC. | $16.32 | 2019 | |
| Currax Pharmaceuticals LLC | $14.91 | 2025 | Contrave |
| Linus Health, INC. | $14.87 | 2023 | |
| Electromed, INC. | $14.05 | 2024 | Smartvest |
| Medtronic Minimed, INC. | $13.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wielenga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.